Calamos Advisors LLC - BRIDGEBIO PHARMA INC ownership

BRIDGEBIO PHARMA INC's ticker is and the CUSIP is 10806XAD4. A total of 45 filers reported holding BRIDGEBIO PHARMA INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.4%.

Quarter-by-quarter ownership
Calamos Advisors LLC ownership history of BRIDGEBIO PHARMA INC
ValueSharesWeighting
Q3 2023$7,605,700
+23.4%
10,000,0000.0%0.04%
+33.3%
Q2 2023$6,162,700
-3.6%
10,000,0000.0%0.03%
-3.2%
Q1 2023$6,392,300
+64.8%
10,000,0000.0%0.03%
+72.2%
Q4 2022$3,878,100
-12.3%
10,000,0000.0%0.02%
-10.0%
Q3 2022$4,422,000
-1.1%
10,000,0000.0%0.02%
+5.3%
Q2 2022$4,472,000
-7.3%
10,000,0000.0%0.02%
+5.6%
Q1 2022$4,826,00010,000,0000.02%
Other shareholders
BRIDGEBIO PHARMA INC shareholders Q3 2023
NameSharesValueWeighting ↓
INHERENT GROUP, LP 39,500,000$15,386,3964.59%
Athyrium Capital Management, LP 20,000,000$7,753,9003.26%
Diameter Capital Partners LP 43,287,000$16,786,9152.61%
Affinity Asset Advisors, LLC 10,000,000$3,895,2901.53%
DeepCurrents Investment Group LLC 39,355,000$14,590,7460.57%
BRAIDWELL LP 42,294,000$16,151,0210.54%
Context Capital Management, LLC 16,458$6,2850.46%
Aequim Alternative Investments LP 31,000,000$11,838,1250.32%
ARISTEIA CAPITAL, L.L.C. 40,816,000$15,586,6100.31%
ABSOLUTE INVESTMENT ADVISERS, LLC 5,000,000$1,875,0000.28%
View complete list of BRIDGEBIO PHARMA INC shareholders